Author(s): Nasir Shariff, Abdul Aleem, Vadim Levin, Ravi V. Desai, Sudip Nanda, Matthew W. Martinez, Stacey J. Smith and Ronald Freudenberger
Page: [53 - 58] Pages: 6
* (Excluding Mailing and Handling)
Heart failure (HF) is a common clinical syndrome characterized by high morbidity and frequent hospitalizations. HF is an independent and major risk factor for venous thromboembolism (VTE) and VTE occurring in patients with HF carries a worse prognosis. The present review will focus on short and long term role of anti-coagulants in prevention of venous thrombosis in HF patients. We will also be discussing the recently investigated and patented anti-coagulants which could have a role in this specific population.
Keywords: Congestive heart failure, prevention, venous thromboembolism, CHRONIC ANTICOAGULATION, ORAL ANTICOAGULATION, PARENTERAL ANTICOAGULATION, Rivaroxaban, Dabigatran, Apixaban, MAGELLAN
